Webinar on May 17, 2019

Starts: 12:00 PM (EDT)
Ends: 12:30 PM (EDT)

Join the Crowell & Moring trade team for a 30-minute update on the U.S.-China trade negotiations, the imposition of tariffs, and the continued escalation of tensions from the White House.  Hear the latest on President Trump’s potential next steps, the status of the product exclusion process for Lists 1, 2, and 3, and how to respond to the recent announcement of List 4, covering virtually all the remaining U.S. imports from China.

Professionals from our legal, policy and political team will discuss potential strategies for companies affected by the Trump tariffs and how to respond – at the White House and before the Office of the U.S. Trade Representative, in the halls of Congress, and in China.  This will be a brief, to-the-point webinar, to be followed by additional analysis and engagement strategies as the Trump tariff war with China continues over the coming weeks and months.

Contact: Tricia Wyse (twyse@crowell.com)

Register
Print:
Email this postTweet this postLike this postShare this post on LinkedIn
Photo of Jim Flood Jim Flood

Jim Flood is a partner in Crowell & Moring’s Washington, D.C. office and assists health care, energy, and financial services clients with legal, legislative, and regulatory issues. He is also chair of the firm’s Government Affairs Group.

A former federal prosecutor and counsel…

Jim Flood is a partner in Crowell & Moring’s Washington, D.C. office and assists health care, energy, and financial services clients with legal, legislative, and regulatory issues. He is also chair of the firm’s Government Affairs Group.

A former federal prosecutor and counsel to Senator Charles E. Schumer (D-NY), Jim has more than 20 years of experience assisting clients facing issues before the White House, Congress, the U.S. Department of Health and Human Services (HHS), the Centers for Medicare & Medicaid Services (CMS), the U.S. Department of Justice (DOJ), the U.S. Drug Enforcement Administration (DEA), the U.S. Food and Drug Administration (FDA), and other federal agencies. He also works with the firm’s Healthcare Group and healthcare fraud practice team to counsel clients on issues related to Medicare, Medicaid, Part D, long-term care, health care fraud, the False Claims Act (FCA), and the anti-kickback statute.

Photo of John Brew John Brew

John Brew is the co-chair of Crowell & Moring’s International Trade Group and a partner in the firm’s Washington, D.C. office. He has extensive experience in import and export trade regulation, and he regularly advises corporations, trade associations, foreign governments, and non-governmental organizations…

John Brew is the co-chair of Crowell & Moring’s International Trade Group and a partner in the firm’s Washington, D.C. office. He has extensive experience in import and export trade regulation, and he regularly advises corporations, trade associations, foreign governments, and non-governmental organizations on matters involving customs administration, enforcement, compliance, litigation, legislation and policy.

John represents clients in proceedings at the administrative and judicial levels, as well as before Congress and the international bureaucracies that handle customs and trade matters. He advises clients on all substantive import regulatory issues handled by U.S. Customs and Border Protection and Immigration and Customs Enforcement, such as classification, valuation, origin, marking, tariff preference programs, other agency regulations, admissibility, import restrictions, quotas, drawback, audits, prior disclosures, penalties, investigations, Importer Self Assessment and Customs-Trade Partnership Against Terrorism programs, importations under bond, the Jones Act, vessel repairs, and foreign trade zone matters.

Photo of Scott Douglas Scott Douglas

Scott Douglas is a senior policy director in Crowell & Moring’s Government Affairs and Health Care groups. His practice focuses on assisting clients with legislative and regulatory issues. Scott uses his significant health care public policy experience to assist health care companies, managed…

Scott Douglas is a senior policy director in Crowell & Moring’s Government Affairs and Health Care groups. His practice focuses on assisting clients with legislative and regulatory issues. Scott uses his significant health care public policy experience to assist health care companies, managed care, long-term care, long-term care pharmacy facilities, trade associations, and others with legislation before the U.S. Congress.

Photo of Tim Shadyac Tim Shadyac

Tim Shadyac is a director in the Government Affairs Group, where he assists clients with legislative and regulatory issues. Tim’s areas of focus include the implementation of the Affordable Care Act and other health reform efforts, the Medicare program, drug pricing policy, and…

Tim Shadyac is a director in the Government Affairs Group, where he assists clients with legislative and regulatory issues. Tim’s areas of focus include the implementation of the Affordable Care Act and other health reform efforts, the Medicare program, drug pricing policy, and the broad impact of politics on health care policy.

Tim has experience working in a variety of health care sector settings. Prior to joining Crowell & Moring, Tim advised clients on a number of health care policy issues at Avalere Health, a D.C.-based health policy consultancy. Throughout his time at Avalere, Tim specialized in matters of importance to the life sciences industry and worked closely with various patient advocacy groups. His work was largely concentrated on issues related to the outcome of presidential and congressional elections, drug pricing policy, and Medicare Part D benefit design. Tim also served in the federal government affairs, public policy, and advocacy groups at Sanofi for nearly four years. There, he monitored and analyzed federal health policy to assess the business impact and developed strategies for response. In his role with the advocacy group, Tim sought opportunities to reflect the patient voice in regulatory guidance and identified opportunities for partnership with patient advocates.